PI Trade Names and Active Ingredients containing Arixtra. 1 Documents available. Need more information on a product? Search the Australian Register of. Mylan manufactures ARIXTRA®* (fondaparinux sodium) Injection, Solution ( Arixtra) in strengths of 25 mg05 mL 5 mgmL5 mg04 mL mgmL75 mg06 mL injection of Arixtra mg in young healthy subjects are provided in Table 1 below: . Arixtra mg once daily following hip fracture surgery, patients were.
|Published (Last):||17 July 2010|
|PDF File Size:||5.26 Mb|
|ePub File Size:||6.50 Mb|
|Price:||Free* [*Free Regsitration Required]|
Discontinue edoxaban before starting fondaparinux, unless these agents are essential. Patients should be instructed to monitor for signs and symptoms of bleeding while taking an SNRI with an anticoagulant medication and to promptly report any bleeding events to the practitioner.
Clinically important bleeding of this type, however, is relatively rare. Major Discontinue pentosan before starting fondaparinux due to the increased arixhra risk, unless these agents are essential.
TGA eBS – Product and Consumer Medicine Information
Fulvestrant IM injections may cause bleeding, bruising, or hematomas in these patients. Moderate Use caution with concomitant use of inotersen and anticoagulants due to the potential risk of bleeding from thrombocytopenia.
Since ginkgo produces clinically-significant antiplatelet effects, it should be used cautiously in patients drugs that inhibit platelet aggregation or pose a risk for bleeding, such as anticoagulants. Your email has been sent. Moderate Concomitant use of eptifibatide and other agents that may affect hemostasis, such as anticoagulants, may be associated with an increased risk of bleeding. Administration of fondaparinux prior to 6 hours following surgery is associated with an increased risk of bleeding.
Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine: Wipe the surface of the injection site with an alcohol swab. All steps to avoid hematoma formation are recommended. Moderate The use of abciximab within 7 days of use an oral anticoagulant is contraindicated unless the patient’s prothrombin time is less than or equal to 1.
Monitor patients who are taking anticoagulants closely and adjust anticoagulation therapy as necessary. Kava Kava, Piper methysticum: The manufacturer recommends cautious use; however, no specific dosage guidelines are available. Severe bleeding events have occurred with ibrutinib therapy including intracranial hemorrhage, GI bleeding, hematuria, and post procedural hemorrhage; some events were fatal.
Major Due to the thrombocytopenic effects of imatinib an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants. The coagulation tests affected by telavancin include prothrombin time PTinternational normalized ratio INRactivated partial thromboplastin time aPTTactivated clotting time, and coagulation based factor Xa tests. Additionally, omega-3 fatty acids contained in cod liver oil may inhibit platelet aggregation. Major During and after therapy, avoid the concomitant use of Yttrium Y ibrutumomab tiuxetan with drugs that interfere with coagulation such as zrixtra the risk of bleeding may be increased.
Moderate Patients on chronic stable doses of anticoagulants, like fondaparinux, should be monitored closely for changes in coagulation parameters when orlistat is prescribed.
The usual duration arixtraa administration is 5 to 9 days; up to 11 additional days has been tolerated.
A clear association with fondaparinux and fetal adverse developmental outcomes has not been demonstrated with available data from published literature and postmarketing reports. The patient should be closely monitored with frequent evaluation of the INR and clinical parameter, and aruxtra dosage of warfarin should be adjusted as necessary until a stable target INR is achieved.
The usual duration of administration is 5 to ;i days; up to 10 days has been administered. Major Platelet aggregation may be impaired by arixtrs serotonin reuptake inhibitors SSRIs due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication in patients receiving anticoagulants, like fondaparinux. Because vorapaxar inhibits platelet aggregation, a potential additive risk for bleeding exists if vorapaxar is given in combination with other agents that affect hemostasis such as anticoagulants.
For storage information, see specific product information within the How Supplied section. Consider delaying the onset of defibrotide treatment until the effects of the antithrombotic agent have abated. Clinicians should consider the risk versus benefit of neuraxial intervention in patients anticoagulated or to be anticoagulated.
Moderate There have been no documented pharmacokinetic interactions of fondaparinux with other drugs. Concomitant anticoagulants may increase the risk of hemorrhage. Bismuth Subsalicylate; Metronidazole; Tetracycline: According to the manufacturer, if oxandrolone therapy is initiated in a patient already receiving warfarin, the dose of warfarin may need to be decreased significantly to reduce the potential for excessive INR elevations and associated risk of serious bleeding events.
ACCP guidelines recommend fondaparinux as an alternative to the preferred agent, low molecular weight heparin, as antithrombotic prophylaxis for patients undergoing total hip or total knee replacement surgery or hip fracture surgery. Moderate Androgens can enhance the effects of anticoagulants.
Moderate An additive risk of bleeding may be seen in thrombocytopenic patients receiving antineoplastic agents and anticoagulants concomitantly.
However, an additive risk of bleeding may be seen in patients receiving platelet inhibitors. Because cilostazol is a platelet aggregation inhibitor, concomitant administration with similar acting drugs could theoretically result in an increased risk of bleeding due to additive pharmacodynamic effects, and combinations of these agents should be approached with caution.
Additive hematological effects are possible as a result of the platelet inhibitory effects of sulfinpyrazone; the sulfide metabolite of sulfinpyrazone appears responsible for this effect.
Arixtra (fondaparinux sodium) dose, indications, adverse effects, interactions from
Coadministration of betrixaban and other anticoagulants may increase the risk of bleeding. Moderate The concomitant use of ibrutinib and anticoagulant agents such as fondaparinux may increase the risk of bleeding; monitor patients for signs of bleeding.
Sodium Hyaluronate, Hyaluronic Acid: